Back HIV/AIDS

HIV / AIDS

IAS 2013: Studies Look at Second-Line Bone Changes, Fractures, and HIV- and HCV-Related Bone Loss

People with HIV experience less bone loss if they switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Other studies showed that HIV infection is associated with increased risk of hip fractures and shed light on different mechanisms of bone loss associated with HIV and hepatitis C.

alt

IAS 2013: No Increase in Risk Behavior among People Taking ART, Meta-Analysis Shows

One of the anxieties in relation to treatment as prevention is that it may discourage people with HIV from using condoms and other prevention methods. However, a meta-analysis has found no increase in risk-taking among people taking antiretroviral treatment, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur last week.

alt

IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels

People with HIV who switch from their current antiretroviral regimen to the NNRTI etravirine (Intelence) maintain undetectable viral load and may see improvement in metabolic parameters, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.alt

HIV Treatment Highlights from IAS 2013 [VIDEO]

Cal Cohen offers a summary of some of the major studies of antiretroviral treatment strategies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last week in Kuala Lumpur.alt

Coverage of the 2013 International AIDS Society Conference

HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.

Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

HIVandHepatitis.com IAS 2013 conference section

7/6/13

alt

 

IAS 2013: Second-line HIV Therapy with NRTIs Linked to Bone Loss [VIDEO]

Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Long-acting GSK1265744 and TMC278-LA Appear Safe and Practical in Early Study

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt